Literature DB >> 12971028

Pharmacokinetics of oral ibuprofen in premature infants.

Pramod Kumar Sharma1, Santosh Kumar Garg, Anil Narang.   

Abstract

Patent ductus arteriosus (PDA) is a frequent complication in premature infants. So far, intravenous indomethacin is the standard mode of medical therapy in such patients but carries a risk of frequently occurring side effects. Ibuprofen, another nonsteroidal anti-inflammatory drug, has also been shown to be efficacious in closing ductus with lesser adverse effects after parenteral administration. However, limited data are available on the pharmacokinetics of intravenous ibuprofen in this population. Nonavailability of parenteral preparation and lack of information regarding pharmacokinetic disposition of ibuprofen in this subgroup of the population led the authors to conduct this pharmacokinetic study with oral ibuprofen. Twenty premature infants with a gestational age of 30.45 +/- 0.33 weeks and a birth weight of 1262.5 +/- 55.4 g (values given as mean +/- SEM) admitted to the neonatal unit were enrolled in this study. Ibuprofen was administered in a single oral dose of 10 mg/kg between 4 and 72 hours postnatally, and blood samples were collected through an indwelling vascular catheter at time 0 and 1, 2, 4, 8, 12, and 24 hours. Ibuprofen plasma concentrations were assayed by high-performance liquid chromatography. There was a large interindividual variability observed for plasma concentrations, elimination half-life (t1/2) (15.72 +/- 3.76 h), and area under the plasma concentration-time curve (AUC0-infinity) (402.60 +/- 79.67 micrograms.h/mL) in these babies. Variables such as gestational age, birth weight, and sex did not affect ibuprofen pharmacokinetics significantly (p > 0.05). Moreover, no correlation could be found between elimination half-life and gestational age (r = 0.02). Ibuprofen pharmacokinetics showed a wide variability in premature infants. The results of the present study warrant revising the oral dosage schedule to achieve comparable plasma concentrations of ibuprofen associated with successful closure of ductus, as reported in earlier studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12971028     DOI: 10.1177/0091270003254635

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

1.  Oral-ibuprofen-induced acute renal failure in a preterm infant.

Authors:  Omer Erdeve; S Umit Sarici; Erkan Sari; Faysal Gok
Journal:  Pediatr Nephrol       Date:  2008-04-30       Impact factor: 3.714

2.  Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus.

Authors:  Gozde Kanmaz; Omer Erdeve; Fuat Emre Canpolat; Serife Suna Oğuz; Nurdan Uras; Nahide Altug; Ben Greijdanus; Uğur Dilmen
Journal:  Eur J Clin Pharmacol       Date:  2012-11-06       Impact factor: 2.953

3.  Pharmacologic, pharmacodynamic, and pharmacokinetic considerations with intravenous Ibuprofen lysine.

Authors:  Edmund V Capparelli
Journal:  J Pediatr Pharmacol Ther       Date:  2007-07

Review 4.  Evidence-based use of indomethacin and ibuprofen in the neonatal intensive care unit.

Authors:  Palmer G Johnston; Maria Gillam-Krakauer; M Paige Fuller; Jeff Reese
Journal:  Clin Perinatol       Date:  2012-01-13       Impact factor: 3.430

5.  Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.

Authors:  Khaled Abduljalil; Xian Pan; Amita Pansari; Masoud Jamei; Trevor N Johnson
Journal:  Clin Pharmacokinet       Date:  2020-04       Impact factor: 6.447

6.  An overview of clinical pharmacology of Ibuprofen.

Authors:  Rabia Bushra; Nousheen Aslam
Journal:  Oman Med J       Date:  2010-07

7.  Comparison of oral ibuprofen with oral indomethacin for PDA closure in Indian preterm neonates: a randomized controlled trial.

Authors:  Sanju Yadav; Sheetal Agarwal; Arti Maria; Ajay Dudeja; N K Dubey; Puneet Anand; Dinesh Kumar Yadav
Journal:  Pediatr Cardiol       Date:  2014-01-17       Impact factor: 1.655

Review 8.  Pharmacological Closure of Patent Ductus Arteriosus: Selecting the Agent and Route of Administration.

Authors:  Sindhu Sivanandan; Ramesh Agarwal
Journal:  Paediatr Drugs       Date:  2016-04       Impact factor: 3.022

9.  Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds.

Authors:  Amit A Somani; Kirstin Thelen; Songmao Zheng; Mirjam N Trame; Katrin Coboeken; Michaela Meyer; Katrin Schnizler; Ibrahim Ince; Stefan Willmann; Stephan Schmidt
Journal:  Br J Clin Pharmacol       Date:  2015-10-30       Impact factor: 4.335

10.  Prediction of glucuronidated drug clearance in pediatrics (≤5 years): An allometric approach.

Authors:  Iftekhar Mahmood
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-02-12       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.